Acadia Pharmaceuticals Inc. (ACAD) News
Follow Acadia Pharmaceuticals Inc. (ACAD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 47 public stories across 17 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
AcadeMedia Q1 Sales Rise 14.1% to SEK 4,679M; Adjusted EBITA SEK 215M
AcadeMedia reported Q1 net sales of SEK 4,679M, up 14.1% year over year, with 4.8% organic growth. Adjusted EBITA was SEK 215M versus SEK 182M a year earlier; the margin was 4.6% versus 4.4%.
EARNINGS | Nov 02, 2026, 06:01 AM UTC
L
Acadia Pharmaceuticals Inc. (ACAD) Patent Allowance Extends Trofinetide Protection to 2041
USPTO issued a Notice of Allowance for Acadia’s patent on weight-banded dosing of trofinetide, expected to protect DAYBUE in the U.S. through Mar 28, 2041, including six months pediatric exclusivity. Current method-of-us
NEWS | Sep 28, 2026, 08:05 PM UTC
L
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled “Methods and Compos
NEWS | Sep 28, 2026, 08:05 PM UTC
L
Weekly Recap: Analysts cut ACAD targets and remlifanserin safety, efficacy
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) saw analysts trim price targets but mostly keep buy ratings as remlifanserin showed favorable safety and emerging 60 mg efficacy over six weeks; the company will continue two lat
NEWS | Sep 28, 2026, 11:03 AM UTC
L
ACADIA Pharmaceuticals Is Maintained at Buy by Deutsche Bank
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 04:34 PM UTC
L
ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets
Acadia Pharmaceuticals (ACAD) stock was in focus Friday after multiple analysts lowered their price targets following topline results from the Phase 2 portion of the RADIANT program evaluating Remlifanserin in Alzheimer'
EQUITY | Sep 25, 2026, 03:23 PM UTC
L
ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 02:53 PM UTC
L
HC Wainwright & Co. maintains Buy rating on ACADIA Pharmaceuticals, $33 price target
HC Wainwright & Co. maintained their Buy rating on ACADIA Pharmaceuticals's stock with a price target of $33.00.The price target implies an upside of 48.8% from the Sep 24 close of $22.18.Key takeaways from the analyst n
EQUITY | Sep 25, 2026, 02:42 PM UTC
L
ACADIA Pharmaceuticals Is Maintained at Market Outperform by Citizens
Ratings actions from Benzinga: GMT) ACADIA Pharmaceuticals Price Target Cut to $33.00/Share From $36.00 by CitizensRatings actions from Benzinga
NEWS | Sep 25, 2026, 12:58 PM UTC
L
Citizens maintains Market Outperform rating on ACADIA Pharmaceuticals, $33 price target
Citizens maintained their Market Outperform rating on ACADIA Pharmaceuticals's stock with a price target of $33.00.The price target implies an upside of 48.8% from the Sep 24 close of $22.18.Key takeaways from the analys
EQUITY | Sep 25, 2026, 12:47 PM UTC
L
ACADIA Pharmaceuticals Price Target Cut to $34.00/Share From $36.00 by BMO Capital
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 12:09 PM UTC
L
ACADIA Pharmaceuticals Price Target Cut to $35.00/Share From $41.00 by Needham
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 10:38 AM UTC
L
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%
Shares of Acadia Pharmaceuticals (ACAD) clocked their worst day since August 2024 on Thursday after remlifanserin, its experimental treatment for hallucinations and delusions in Alzheimer’s disease psychosis, missed the
EQUITY | Sep 24, 2026, 09:52 PM UTC
L
Acadia reports Phase 3-enabling Phase 2 topline for remlifanserin in AD psychosis; 60 mg shows nominal CGI-S significance
Acadia announced Phase 3-enabling Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis, with 60 mg showing nominal significance on CGI-S and favorable safety.Key Highlights:Original SEC Filing: ACAD
REGULATION | Sep 24, 2026, 09:14 PM UTC
L
ACADIA Pharmaceuticals Price Target Cut to $33.00/Share From $40.00 by Citigroup
Ratings actions from Benzinga: GMT) ACADIA Pharmaceuticals Is Maintained at Buy by CitigroupRatings actions from Benzinga
NEWS | Sep 24, 2026, 06:11 PM UTC
H
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 350 points on Thursday. The Dow traded down 0.70% to 51,153.35 while the NASDAQ dipped 0.70% to 26,746.39. The S&P 500 also fell, d
LIVE | Sep 24, 2026, 04:02 PM UTC
L
ACADIA Pharmaceuticals Price Target Maintained With a $41.00/Share by Needham
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 02:44 PM UTC
L
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study
Acadia Pharmaceuticals NASDAQ:ACAD said on Thursday its experimental drug for psychosis associated with Alzheimer's missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions i
EQUITY | Sep 24, 2026, 11:59 AM UTC
L
Acadia Pharma Shares Drop After Remlifanserin Trial Narrowly Misses Primary Endpoint
By Chris WackShares of Acadia Pharmaceuticals were lower after the company said the Phase 3 enabling topline results for its ongoing clinical trial program evaluating remlifanserin for the treatment of hallucinations and
EQUITY | Sep 24, 2026, 11:34 AM UTC
L
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results From Phase 2 Radiant Study Of Remlifanserin For The Treatment Of Alzheimer’S Disease Psychosis
Acadia Pharmaceuticals Inc. NASDAQ:ACAD
NEWS | Sep 24, 2026, 11:08 AM UTC
L
Acadia Pharmaceuticals Inc. (ACAD) Posts Phase 2 ADP Topline: Primary p=0.0603, Secondary p=0.0077
Acadia reported Phase 2 topline for remlifanserin in Alzheimer’s disease psychosis: 60 mg showed SAPS-H+D effect size 0.26 (p=0.0603) and CGI-S-ADP effect size 0.37 (p=0.0077, nominal). Safety similar to placebo. Phase 3
NEWS | Sep 24, 2026, 11:01 AM UTC
L
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinati
NEWS | Sep 24, 2026, 11:00 AM UTC
L
ACADIA Pharmaceuticals - On Aug 24, Court Preliminarily Approves Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action - SEC Filing
Acadia Pharmaceuticals Inc. NASDAQ:ACAD
REGULATION | Sep 11, 2026, 09:25 PM UTC
L
Acadia Pharmaceuticals reaches preliminary settlement in derivative suit; $1.5M fees, four-year governance reforms
Acadia Pharmaceuticals reached a preliminary court-approved settlement of a stockholder derivative action requiring adoption of corporate governance reforms and a $1,500,000 fee for stockholders' counsel.Key Highlights:O
REGULATION | Sep 11, 2026, 09:24 PM UTC
L
ACAD: Record growth and profitability achieved, fueled by quality, expansion, and acquisitions
ACAD: Record growth and profitability achieved, fueled by quality, expansion, and acquisitions
EQUITY | Aug 31, 2026, 08:20 AM UTC
L
Academedia Q4 net sales rise 10.6% to SEK 5,658m
Academedia reported Q4 net sales increasing 10.6% to SEK 5,658 million.
EQUITY | Aug 31, 2026, 05:03 AM UTC
L
ACAD: Sales and profit rose on strong international growth and acquisitions, with margins improving
ACAD: Sales and profit rose on strong international growth and acquisitions, with margins improving
EQUITY | Aug 31, 2026, 05:01 AM UTC
L
AcadeMedia interim report for July 2025–June 2026
AcadeMedia published its interim report for the period July 2025 through June 2026.
EQUITY | Aug 31, 2026, 05:00 AM UTC
M
European Commission approves ACAD's DAYBU for Rett syndrome
ACAD says the European Commission approves DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome in the European Union.
REGULATION | Aug 24, 2026, 01:32 PM UTC
L
ACAD PT Raised to $41 by Needham
Needham raises ACAD price target to $41 from $38
EQUITY | Aug 12, 2026, 10:47 AM UTC
L
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B Est
ACADIA Pharmaceuticals (NASDAQ: ACAD ) raises FY2026 sales outlook from $1.220 billion-$1.280 billion to $1.240 billion-$1.300 billion vs $1.242 billion estimate.
EARNINGS | Aug 04, 2026, 08:33 PM UTC
H
US Stocks: Earnings After Market
Multiple US companies report earnings
EARNINGS | Aug 04, 2026, 09:07 AM UTC
H
US Stocks: Earnings After Market
Multiple US companies report earnings
EARNINGS | Aug 03, 2026, 08:49 PM UTC
L
ACAD Affirm Outperform rating and increase PT to $36 @ BMO
ACAD Affirm Outperform rating and increase PT to $36 @ BMO
EQUITY | Jul 21, 2026, 12:46 PM UTC
L
ACAD Remlifanserin Deep Dive: Previewing ADP, Where Stifel Are Skeptical But Acknowledge an Upside Biased Stock Risk/Reward @ Stifel
ACAD Remlifanserin Deep Dive: Previewing ADP, Where Stifel Are Skeptical But Acknowledge an Upside Biased Stock Risk/Reward @ Stifel
EQUITY | Jul 21, 2026, 11:27 AM UTC
L
ACAD Acadia Pharmaceuticals receives FDA fast track designation for remlifanserin in Alzheimer's Disease psychosis Acadia Pharmaceuticals
ACAD Acadia Pharmaceuticals receives FDA fast track designation for remlifanserin in Alzheimer's Disease psychosis Acadia Pharmaceuticals - completes radiant phase 2 enrollment; topline results expected September-october
REGULATION | Jul 20, 2026, 01:05 PM UTC
H
Acadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm's price target on Acadia Pharmaceuticals to $36 from $29 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotec
RATES | Jul 07, 2026, 11:16 AM UTC
L
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
Experienced global HR leader joins Acadia to advance people strat
EQUITY | Jul 06, 2026, 01:04 PM UTC
L
B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $29 to $30.
EQUITY | Jun 30, 2026, 05:36 PM UTC
M
Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $32 to $36.
EQUITY | Jun 29, 2026, 01:36 PM UTC
H
Oil Falls 4%
Crude oil prices fall 4% to $69.05, while US consumer sentiment rises to 49.5 in June
COMMODITIES | Jun 26, 2026, 04:17 PM UTC
M
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Friday. Shares of Apogee Enterprises In c (NASDAQ: APOG ) rose sharply after the company reported better-than-expected first-quarter financ
EARNINGS | Jun 26, 2026, 01:39 PM UTC
H
ACAD +17% on EU Approval
ACAD rises 17% premarket after DAYBU receives European Union approval recommendation from CHMP
EQUITY | Jun 26, 2026, 01:08 PM UTC
H
US Premarket Movers
Select US stocks are moving premarket due to various announcements and earnings reports
EQUITY | Jun 26, 2026, 12:37 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Friday's pre-market session, with gainers including Quantum Cyber and INVO Fertility, and losers including Creative Medical Tech and Omeros
EQUITY | Jun 26, 2026, 12:05 PM UTC
L
ACAD DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
ACAD DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
EQUITY | Jun 26, 2026, 10:53 AM UTC